Samjin Pharmaceuticals Co., Ltd. (KRX:005500)

South Korea flag South Korea · Delayed Price · Currency is KRW
18,640
+70 (0.38%)
At close: Jun 5, 2025, 3:30 PM KST
-5.38%
Market Cap 228.48B
Revenue (ttm) 274.03B
Net Income (ttm) 21.89B
Shares Out 12.26M
EPS (ttm) 1,727.82
PE Ratio 10.79
Forward PE 9.36
Dividend 800.00 (4.29%)
Ex-Dividend Date Dec 27, 2024
Volume 22,281
Average Volume 19,441
Open 18,570
Previous Close 18,570
Day's Range 18,420 - 18,750
52-Week Range 16,590 - 21,500
Beta 0.22
RSI 75.41
Earnings Date May 15, 2025

About Samjin Pharmaceuticals

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clin... [Read more]

Sector Healthcare
Founded 1968
Employees 586
Stock Exchange Korea Stock Exchange
Ticker Symbol 005500
Full Company Profile

Financial Performance

In 2022, Samjin Pharmaceuticals's revenue was 274.03 billion, an increase of 9.58% compared to the previous year's 250.07 billion. Earnings were 21.89 billion, a decrease of -22.92%.

Financial Statements

News

There is no news available yet.